Topoisomerase II inhibitor-related acute myeloid leukaemia.
CH Pui, MV Relling - British journal of haematology, 2000 - search.ebscohost.com
CH Pui, MV Relling
British journal of haematology, 2000•search.ebscohost.comPresents information on acute myeloid leukemia (AML) after topoisomerase II inhibitor
therapy. Pathogenesis of AML; Clinical and biological characteristics; Risk factors for the
development of topoisomerase II inhibitor-related AML; Treatment responsiveness of the
complication.
therapy. Pathogenesis of AML; Clinical and biological characteristics; Risk factors for the
development of topoisomerase II inhibitor-related AML; Treatment responsiveness of the
complication.
Abstract
Presents information on acute myeloid leukemia (AML) after topoisomerase II inhibitor therapy. Pathogenesis of AML; Clinical and biological characteristics; Risk factors for the development of topoisomerase II inhibitor-related AML; Treatment responsiveness of the complication.
search.ebscohost.com
